Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.04
-1.15 (-6.32%)
At close: Nov 22, 2024, 4:00 PM
17.98
+0.94 (5.52%)
After-hours: Nov 22, 2024, 7:27 PM EST
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 76 employees as of December 31, 2023. The number of employees decreased by 7 or -8.43% compared to the previous year.
Employees
76
Change (1Y)
-7
Growth (1Y)
-8.43%
Revenue / Employee
$90,171
Profits / Employee
-$2,121,908
Market Cap
2.25B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 76 | -7 | -8.43% |
| Dec 31, 2022 | 83 | -7 | -7.78% |
| Dec 31, 2021 | 90 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Addus HomeCare | 34,846 |
| CONMED | 4,000 |
| UFP Technologies | 3,093 |
| iRhythm Technologies | 2,000 |
| Alignment Healthcare | 1,536 |
| LeMaitre Vascular | 630 |
| Wave Life Sciences | 268 |
| Keros Therapeutics | 136 |
CNTA News
- 10 days ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire
- 2 months ago - Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire